Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Gene Therapy
FerGene gene therapy firm formed with $570 million in funding
by Lisa M. Jarvis
November 30, 2019
| A version of this story appeared in
Volume 97, Issue 47
FerGene has launched with more than $570 million in funding from Ferring Pharmaceuticals and Blackstone Life Sciences to bring to market nadofaragene firadenovec, a bladder cancer gene therapy. Most of the money—$400 million—comes from Blackstone, an investment firm. Ferring licensed the adenovirally mediated interferon alfa-2b gene therapy last year from FKD Therapies, which had bought it from Merck & Co. in 2011. Ferring later filed for US approval of the treatment.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X